Leveragen’s Singularity Sapiens Mouse platform, which generates fully human single-domain antibodies through in vivo maturation, offers a unique advantage in biologics research by enabling high diversity, strong developability, and broad epitope coverage. This collaboration grants Propeller Bio access to Leveragen’s proprietary models, potentially accelerating the discovery of novel antibody-based therapies, including bispecifics, antibody-drug conjugates (ADCs), and CAR-T treatments.
Biopharmaceutical companies may take interest in the Singularity platform’s versatility, as it supports multiple therapeutic formats and could streamline the traditionally complex process of antibody discovery. Investors and researchers might see value in the partnership’s potential to yield high-quality biologics with improved translational outcomes.
Image Credit: Leveragen and Propeller Bio
